Research Progress on the Molecular Mechanism of Metformin Regulating AMPK Signaling Pathway in Inhibiting Liver Cancer
OncoTargets and Therapy · 2026-02 · Volume 19 · 1-19
DOI: 10.2147/ott.s572872 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift OncoTargets and Therapy, 2026-02. Verfasst von Hong Bin Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Radiology Department, Affiliated Fourth Hospital, Harbin Medical University, Harbin, Heilongjiang, People's Republic of China. Die Arbeit nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Liver cancer is one of the common malignant tumors worldwide and ranks among the top in cancer mortality statistics. In recent years, metformin, as a first-line drug with significant efficacy and low cost, has been widely used in clinical practice for the treatment of diabetes. Now, due to its potential inhibitory effect on cancer cells, it has received extensive attention. In view of this, a large number of studies have focused on the mechanisms by which metformin affects Liver carcinoma, with the AMPK pathway being particularly favored. This is because the AMPK pathway plays a significant role in autophagy, cell cycle arrest, inhibition of tumor angiogenesis, and suppression of epithelial-mesenchymal transition. To this end, we reviewed relevant research literature and systematically explored the mechanism of metformin's treatment of liver cancer through the AMPK pathway and its potential clinical applications. These studies provide an important basis for understanding the potential role of metformin in the treatment of liver cancer and provide important reference for future research on its new mechanisms and its clinical application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Interventional Radiology Department, Affiliated Fourth Hospital, Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Zitieren
APA
Zhang, H. B., Yan, Y., Pang, J. P., Kong, M. T., & Zhu, Q. K. (2026). Research Progress on the Molecular Mechanism of Metformin Regulating AMPK Signaling Pathway in Inhibiting Liver Cancer. OncoTargets and Therapy, Volume 19, 1-19. https://doi.org/10.2147/ott.s572872
Vancouver
Zhang HB, Yan Y, Pang JP, Kong MT, Zhu QK. Research Progress on the Molecular Mechanism of Metformin Regulating AMPK Signaling Pathway in Inhibiting Liver Cancer. OncoTargets and Therapy. 2026;Volume 19:1-19. doi:10.2147/ott.s572872
BibTeX
@article{Zhang2026,
author = {Zhang, Hong Bin and Yan, Yan and Pang, Jin Peng and Kong, Meng Ting and Zhu, Qian Kun},
title = {Research Progress on the Molecular Mechanism of Metformin Regulating AMPK Signaling Pathway in Inhibiting Liver Cancer},
journal = {OncoTargets and Therapy},
year = {2026},
volume = {Volume 19},
pages = {1--19},
doi = {10.2147/ott.s572872}
}
EUVIMED